A

Alpine Immune Sciences Inc
F:34LA

Watchlist Manager
Alpine Immune Sciences Inc
F:34LA
Watchlist
Price: 59 EUR Market Closed
Market Cap: 4B EUR

Intrinsic Value

34LA's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one 34LA stock under the Base Case scenario is 8.96 EUR. Compared to the current market price of 59 EUR, Alpine Immune Sciences Inc is Overvalued by 85%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

34LA Intrinsic Value
8.96 EUR
Overvaluation 85%
Intrinsic Value
Price
A
Base Case Scenario

Valuation History
Alpine Immune Sciences Inc

Valuation History Unavailable

Historical valuation for 34LA cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Alpine Immune Sciences Inc
F:34LA
US
Biotechnology
Market Cap
3.9B EUR
IPO
Jun 17, 2015
US
Biotechnology
Market Cap
3.9B EUR
IPO
Jun 17, 2015
Price
€false
EPS
$false
Company Overview
Loading...
Business Segments
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about 34LA?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Alpine Immune Sciences Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Alpine Immune Sciences Inc

Current Assets 308.3m
Cash & Short-Term Investments 305.7m
Receivables 543k
Other Current Assets 2m
Non-Current Assets 65.4m
Long-Term Investments 56.5m
PP&E 8.7m
Other Non-Current Assets 269k
Efficiency

Free Cash Flow Analysis
Alpine Immune Sciences Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Alpine Immune Sciences Inc

Revenue
56.5m USD
Operating Expenses
-107.9m USD
Operating Income
-51.4m USD
Other Expenses
14.5m USD
Net Income
-36.8m USD
Fundamental Scores

34LA Profitability Score
Profitability Due Diligence

Alpine Immune Sciences Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional 1-Year Revenue Growth
ROE is Increasing
ROIC is Increasing
31/100
Profitability
Score

Alpine Immune Sciences Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

34LA Solvency Score
Solvency Due Diligence

Alpine Immune Sciences Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
69/100
Solvency
Score

Alpine Immune Sciences Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

34LA Price Targets Summary
Alpine Immune Sciences Inc

There are no price targets for 34LA.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

Alpine Immune Sciences Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for 34LA is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one 34LA stock?

The intrinsic value of one 34LA stock under the Base Case scenario is 8.96 EUR.

Is 34LA stock undervalued or overvalued?

Compared to the current market price of 59 EUR, Alpine Immune Sciences Inc is Overvalued by 85%.

Back to Top